AATMAJ vs BALAXI: Stock Comparison
BALAXI PHARMA is the larger company by market capitalisation. AATMAJ shows faster revenue growth, while BALAXI PHARMA shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AATMAJ leads 4; BALAXI leads 6 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AATMAJ | BALAXI |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | AATMAJ | BALAXI |
|---|---|---|
| Live Price | — | ₹23.41 |
| Day Change | — | -0.59% |
| Volume | — | 7,765 |
| 52-Week High | — | ₹47.71 |
| 52-Week Low | — | ₹15.2 |
| Distance from 52W High | — | -50.93% |
Valuation
| Metric | AATMAJ | BALAXI |
|---|---|---|
| Market Cap | ₹44 Cr | ₹130 Cr |
| P/E Ratio | — | 12.63x |
| P/B Ratio | — | 0x |
| EPS | ₹0.32 | ₹0.45 |
| Book Value | ₹22.49 | ₹45.12 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | AATMAJ | BALAXI |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -25.76% |
| EPS Growth (TTM YoY) | 0% | -58.44% |
| Qtr Sales Growth | 124.95% | -80.68% |
| Qtr Profit Growth | 39.69% | -196.59% |
Profitability & Leverage
| Metric | AATMAJ | BALAXI |
|---|---|---|
| ROE | 1.4% | 3.87% |
| ROCE | 2.86% | 4.42% |
| Net Margin | 0% | 0.52% |
| Operating Margin | 9.66% | 12.03% |
| Debt to Equity | 0.41x | 0.25x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | AATMAJ | BALAXI |
|---|---|---|
| Promoter Holding | 64.33%▲ 0.57 pp | 65.99% |
| FII Holding | 0% | 0% |
| DII Holding | 0% | 2.56% |
| Public Holding | 35.67%▼ 0.57 pp | 31.45% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AATMAJ and BALAXI PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.